AI주식인사이트AI Stock Insight
C

SK바이오사이언스

302440KOSPI기초 의약물질 제조업

44.7 / 100

Reference Date: 2026-07-24

Financial Score13.0 / 40
News Sentiment18.7 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 7.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SK Bioscience, established in 2018 as a spin-off from SK Chemicals, focuses on vaccine development and global CDMO services. Key products include cell-culture influenza vaccines like 'SkyCellflu' and the COVID-19 vaccine 'SkyCovion,' which received WHO PQ certification and global approvals. The company also provides CDMO services, collaborating with global pharmaceutical firms to produce and develop vaccines.

Number of Employees

1,129people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
1.30Industry Average 1.262.5Point

Higher than industry avg (caution)

ROE
-2.77Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
29.06Industry Average 6.620.0Point

4.4x industry avg (risky)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲57.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼522.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.4% (declining, 3yr)

Detailed News Sentiment

18 totalPositive 13Neutral 5Negative 0Average Sentiment Score 74.7

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 33,650Won52-week high 60,10052-week low 32,750
1-month return1.0Point

1m -7.43% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0